War on Cancer: Gilead & Kite Unveil Potentially Game-Changing Data at Global Summits!
- Triple-Negative Breast Cancer: Groundbreaking Phase 3 results for Trodelvy plus Keytruda in previously untreated, aggressive TNBC1, 3.
- Brain Cancer Breakthrough: Pioneering early data from a novel dual-target CAR T-cell therapy tackling recurrent glioblastoma1, 3.
- Multiple Myeloma Hope: Updated, promising findings for anito-cel in patients with relapsed/refractory multiple myeloma1, 3.
The fight against cancer is poised for a seismic shift as Gilead Sciences and Kite prepare to unleash a torrent of potentially transformative data at the upcoming 2025 ASCO and EHA oncology and hematology congresses. More than 20 abstracts will showcase their relentless pursuit of innovation, targeting some of the most formidable cancers known to medicine.
In a highly anticipated late-breaking presentation, the world will see detailed results from the ASCENT-04 study, pitting a powerful combination of Trodelvy and Keytruda against current standards in first-line metastatic triple-negative breast cancer—a notoriously aggressive foe1, 3. Simultaneously, a new dawn may be breaking for brain cancer patients, with Kite collaborators unveiling Phase 1 results for a daring, dual-target CAR T-cell therapy aimed directly at recurrent glioblastoma, a disease that has long defied significant advances1, 3.
For those battling relapsed/refractory multiple myeloma, updated findings from the iMMagine-1 study on anitocabtagene autoleucel (anito-cel) offer a fresh wave of optimism1, 3. This cutting-edge CAR T-cell therapy, developed with Arcellx, continues to show promise. These presentations, alongside early data for novel pipeline therapies like KITE-363, underscore a deep commitment to "transform how cancer is treated," as stated by Gilead's Chief Medical Officer, Dietmar Berger. From solid tumors to blood cancers, Gilead and Kite are not just presenting data; they are heralding a new era of hope and innovation in the relentless war against cancer2, 7.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.